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Around 1 % of the Western population suffers from coeliac disease (CD), a food-
related inflammatory disorder of the small intestine caused by the ingestion of gluten 
in genetically predisposed individuals. This prevalence is still increasing [1,2]. 
Recently, a new and less well defined gluten (or wheat) related syndrome has emerged 
that seems to be unrelated to coeliac disease, named gluten sensitivity (GS). The so-
called ‘gluten-free diet’ appears to improve significantly the health condition of these 
GS patients. In some studies, a direct correlation was found with gluten consumption 
[3], whereas other authors pinpoint on protein compounds that are co-extracted with 
gluten, such as amylase trypsin inhibitors (ATIs) [4]. The prevalence of GS is 
estimated at 5 - 10 % of the western population [5], but a clear definition is lacking, 
and no biomarkers and epidemiological data are available as well to confirm this 
percentage anyhow. However, the fact that the gluten-free market goes mainstream 
and is growing to several billion Euro sales annually reflects a steady trend that goes 
beyond coeliac disease [6].  
The major difference between CD and GS is in the small intestine where cases of GS 
do not show the CD-specific villous atrophy. Other symptoms of CD and GS are 
similar and are highly diverse in both, including chronic abdominal pain, diarrhoea, 
and growth retardation in children, and chronic fatigue and headache, bowel 
complaints, reduced fertility, dermatitis herpetiformis, osteoporosis, nerve and brain 
(behaviour) disorders, increased risk of intestinal cancer in adults, to mention the most 
common ones. This wide variety of symptoms largely hampers good diagnosis. As a 
result, only 10 - 20 % of the CD population has been properly diagnosed, as will also 
be an unknown but possibly minor fraction of the GS population. This implies that the 
vast majority of the individuals with CD and GS are unaware of their disease. They 
continue their daily consumption of large amounts of gluten and worsen their health 
status and health perspectives, which is a major concern.  
The high food industrial qualities of wheat gluten have led, in recent decades, to a 
steady increase in its food-industrial applications. A survey in Australia of more than 
10,000 supermarket items detected wheat in almost 30 % of labelled products [7]. In 
some of these products, the connection to wheat was visible and even proactively 
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marketed; in other products, it was invisible. The latter group consisted not only of 
processed foods, but also foods that are not commonly associated with wheat, such as 
canned vegetables, milk, meat and even seafood and medicines; obviously, a big 
problem for individuals with CD and GS. Therefore, because of the apparent increase 
in the prevalence of wheat- and gluten-related symptoms, new applications of wheat 
gluten (in natural or modified forms), particularly in non-cereal-based food products 
should be considered deliberately, and the current use of wheat and gluten in saleable 
foods should be re-evaluated. Labelling of packed food products (according to 
Directive 2003/89/EC) [8] is helpful, but only for diagnosed individuals. As 
mentioned, these form only a minority of the patients. 
This creates a challenge. The question now arises how the food industrial quality of 
wheat and its gluten can be maintained while reducing or, even better, eliminating 
negative health effects. 
Two strategies can be put forward: 
1. Reduction of (coeliac) immunogenic proteins in regular wheat- and gluten-
containing foods. As the induction of CD appears to be related to, amongst 
others, the dose of exposure to gluten-derived epitopes, we assume that every 
reduction in the consumption of harmful (CD-immunogenic) gluten will 
contribute to a general reduction of the prevalence of the disease(s) and of 
symptom severity in the population. This will, therefore, in time, benefit the 
general population, including the non- and wrong-diagnosed groups of CD and 
GS individuals. 
2. Production of guaranteed safe and healthy foods for individuals that are already 
diagnosed with CD and have to follow a life-long gluten-free diet. Such food 
products will also be of benefit for people with GS.  
Strategy 1 can be performed in two ways:  
a) The systematic application of well-characterised low CD-immunogenic wheat 
varieties, which are currently under development [9,10] (Fig. 1). To achieve this goal, 
low CD-immunogenicity with regard to coeliac disease epitopes should become an 
additional wheat breeders’ aim. The currently developed immunological and molecular 
(e.g. deep 454-sequencing of expressed gluten genes, Fig. 2) tools for quantification of 
toxicity and for molecular marker-assisted breeding (Salentijn et al., in preparation) 
will be very helpful in the development of low CD-immunogenic wheat varieties. 
Until being mainstream, such varieties will need to be processed in separate and 
strictly controlled production lines. This is a long-term approach. 
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Fig. 1. Low toxic wheat (tetraploid accession Dibillik Sinde and hexaploid variety 
Minaret compared to variety Toronto) 
 
 
Fig. 2. Deep sequencing 
b) The general reduction of gluten in food products, comparable to the current goals of 
reduction of salt, fat and carbohydrates. This may include the development of 
technologically more efficient but less toxic gluten. With regard to industrial and 
technological quality characteristics, the glutenin component of gluten is much more 
relevant than the gliadin component. As the gliadins contain most of the coeliac 
disease epitopes, separation of specifically the glutenin fraction from the gluten may 
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result in an economically and technologically profitable product with significantly 
reduced CD immunogenicity (van den Broeck et al. in preparation) (Fig. 3). This 
approach requires a change in the current industrial gluten production. 
 
Fig. 3. Electrophoresis of 10 μg HMW-GS isolated from gluten of bread wheat 
variety Bussard 
Strategy 2 may include:  
a) The application of alternative processing techniques that eliminate (break down) the 
CD epitopes, such as sourdough fermentation [11,12]. 
b) The production of completely safe gluten proteins, either recombinant or by 
processing, based on currently gained knowledge on the elimination of the toxic 
fragments (Fig. 4) [13,14].  
 
 
Fig. 4. Schematic diagram of a new non-immunogenic gluten gene [14] 
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c) Alternative cereals which are safe and also may provide sufficient technological 
properties. Among these cereals, oats are currently the best possible replacement for 
wheat, rye and barley. According to EC Regulation 41/2009 [15], oat products 
containing less than 20 ppm gluten are now allowed to be sold as gluten-free. In 
addition, oats contain many healthy components (especially beta-glucans) and thus can 
serve as an important supplement to the patient’s daily diet. Although a very low 
minority of CD patients may be sensitive to oats, several CD-patient societies in 
Europe promote the opportunistic approach: just try, and introduce oats in your diet 
gradually. One of the most beloved oat products may become the gluten-free oat 
bread. This requires new baking technologies and recipes (Londono et al., in 
preparation) (Fig. 5). Currently, the first generation of pure oat bread is on the market 
in The Netherlands (www.broodpakket.nl) 
 
Fig. 5. Oat bread 
In conclusion, a variety of alternative strategies are under development to lower the 
level (the burden) to the consumers of gluten in foods in general, as well as to 
eliminate CD-immunogenic epitopes in particular, aiming at significantly fewer and 
less severe cases of CD and GS. 
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